U.S. regulators approve 1st generic version of an under-the-tongue treatment for opioid addiction
U.S. regulators have approved the first generic version of an under-the-tongue film for treating opioid addiction.
The Food and Drug Administration on Thursday approved a generic version of Suboxone, a film strip that dissolves under the tongue. Used daily, it reduces withdrawal symptoms, cravings for opioids and the high from abusing them.
The medication combines buprenorphine and naloxone. It’s used along with counseling and other behavioral therapy.
The generic version will be sold by partners Mylan N.V. and Dr. Reddy’s Laboratories SA. They didn’t immediately respond to questions about when their version will be available or what it will cost.
Most Read Business Stories
- Flawed analysis, failed oversight: How Boeing, FAA certified the suspect 737 MAX flight control system | Times Watchdog
- With regulators wary, Boeing faces more hurdles to restore 737 MAX fleet
- Bill Gates joins Jeff Bezos as the only two members of the $100 billion club
- Delegating aircraft safety assessments to Boeing is nothing new for the FAA
- Chief of Starbucks' high-end initiative takes a 'coffee break' leave
Brand-name Suboxone film costs about $200 a month without insurance.
The FDA said the approval was aimed at making the treatment available to more people.